WT1基因在白血病患者中的表达及临床意义  

Expression of Wilms' Tumor Gene(WT1) in Leukemia Patients and Its Clinical Significance

作　　者：聂波[1] 杨弘[1] 武坤[1] 李云涛[1] 李丽银[1] 

机构地区：[1]昆明医科大学第一附属医院血液内科,云南昆明650032

出　　处：《昆明医科大学学报》2016年第4期80-83,共4页Journal of Kunming Medical University

基　　金：云南省科技厅-昆明医科大学联合专项基金资助项目(2014FB027)

摘　　要：目的研究WT1基因在白血病患者中的表达及其临床意义.方法运用RT-PCR方法检测WT1基因在200例白血病患者中的表达.结果急性髓细胞白血病(AML)和急性淋巴细胞白血病(ALL)WT1表达阳性率分别为79.2%(76/96)和57.1%(32/56).慢性粒细胞白血病(CML)慢性期WT1表达均阴性,急变期57.1%(8/14)表达阳性.WT1阳性患者化疗缓解率低于阴性患者(分别为55.7%和85.4%,P<0.05).结论WT1在白血病患者中高表达,可作为临床评估预后、检测微小残留病(MRD)的标志.Objective To evaluate the expression of WT1 gene in leukemia patients and its clinical implication.Me thod Nest RT- PCR technique was applied to examine WT1 gene expression in 200 patients with leukemia.Re s ults The WT1 m RNA positive rates in acute myeloid leukemia and lymphoblastic leukemia were79.2%（76/96） and 57.1%（32/56）. In chronic myeloid leukemia, WT1 m RNA was undetectable in chronic phase; but was revealed in 8 of 14 patients at blast crisis（57.1%）. The rate of remission in the patients positive for WT1 was lower than in those negative for WT1（55.7% vs 85.4%,P〈0.005）.Conclus ion The WT1 is highly expressed in the majority of the patients with leukemia and thus is involved in human leukemogenesis. WT1 may be a new prognostic factor and a panleukemia marker for the detection of MRD.

关 键 词：白血病 WT1基因 微小残留病 

分 类 号：R733.7[医药卫生—肿瘤]